USPTO serial 87048078
MH MOLECULAR HEALTH
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 13, 2021
- Examiner
- HISER, CHARLES
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with MH MOLECULAR HEALTH?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $2,144*
Plus Government fees of $1,950
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Peter T. Wakiyama
Peter T. Wakiyama Troutman Pepper Hamilton Sanders LLP3000 Two Logan SquarePhiladelphia, PA 19103UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Downloadable computer databases containing information in the fields of medicine, health care, genomics, bioinformatics, pharmaceuticals, life sciences and biotechnology; downloadable computer databases containing medical and health information or records about or relating to humans; downloadable computer software for accessing, organizing, indexing, ranking, integrating, linking, referencing, synthesizing, interpreting and analyzing information from databases in the fields of medicine, health care, genomics, pharmaceuticals, life sciences and biotechnology and databases containing medical and health information or records about or relating to humans, including biomedical databases containing information about clinical, genomic, molecular, scientific and patient specific data, in particular information that clinicians and researchers enable to interpret complex molecular and genomic patient information; downloadable computer databases in the field of biomedical information, in particular links to external reference databases, in particular for the alignment and integration of biomedical information; downloadable computer software and algorithms for storing and sorting biomedical information, in particular links to external reference databases, in particular for the alignment and integration of biomedical information, updating and expanding global reference data sources across diverse medical disciplines and for allowing the immediate access to biomedical information; downloadable computer databases containing biomedical information in form of human genome sequences, information about indication and classifications of diseases, biomarkers, information about the molecular mechanism of action of drugs, their targets, metabolizing enzymes, information about scientific publications from diverse areas of biomedicine drug-to-drug interactions and the status of drug development; downloadable computer software and algorithms for authorizing or providing access to biomedical databases, in particular application software, interface software, software drives, data communication software, interactive computer software; downloadable computer software and software components for serving domain-specific user demands; downloadable mobile applications for mobile devices, such as smart phones and tablet computers, for accessing, organizing, synthesizing, indexing, ranking, integrating, linking, referencing, interpreting and analyzing information from databases in the fields of medicine, health care, genomics, bioinformatics, pharmaceuticals, life sciences and biotechnology and databases containing medical and health information or records about or relating to humans | ACTIVE | Nov 1, 2019 |
| 035 | Business consulting and research services for employers in the field of employee benefits in the nature of offering medical and health care plans to employees and their family members and domestic partners for medical and health care diagnostic and treatment support programs | ACTIVE | Nov 1, 2019 |
| 036 | Financial administration of programs and services for payment and reimbursement of employee benefits in the nature of medical and health care diagnostic and treatment support programs, for employees and their family members and domestic partners | ACTIVE | Nov 1, 2019 |
| 038 | Providing access to searchable databases containing medical, pharmaceutical, biological, clinical and genomic information and medical and health information or records, molecular test results and patient specific data about or relating to humans for scientific research purposes; providing access to non-downloadable computer software and algorithms for use by physicians, clinicians and other healthcare professionals, laboratory personnel, consultants, scientists and other researchers for medical diagnostic and treatment and drug safety research and drug or pharmaceuticals or other treatment discovery, research and development; providing access to non-downloadable software and algorithms for retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data, diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, records or data, and patient specific data, molecular test results, data from clinical studies, and scientific research for medical diagnostic and treatment research and drug or pharmaceuticals or other treatment discovery, research and development purposes; providing access to non-downloadable computer software and algorithms for use by physicians, clinicians and other healthcare professionals, laboratory personnel, consultants, scientists and other researchers for medical diagnostic and treatment purposes; providing access to software and algorithms for retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data, diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, records or data, and patient specific data, molecular test results, data from clinical studies, and scientific research for medical diagnostic and treatment purposes; providing access to databases containing medical, pharmaceutical, biological, clinical, molecular, sequencing and genomic information, disease information, biomarker information and medical or health information or records about or relating to humans and patient specific data, molecular test results, and scientific research for medical diagnostic and treatment purposes | ACTIVE | Nov 1, 2019 |
| 042 | Scientific consulting and research services in the fields of health care, medicine, life sciences, biotechnology, pharmaceuticals, bioinformatics, genomics and pharmaceuticals and pharmaceutical safety for scientific research purposes; Scientific consulting and research services for the retrieval, integration, correlation, analysis and interpretation of genomic data, sequencing data, and molecular data, disease, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, records or data, and patient specific data, molecular test results, data from clinical studies, and scientific research for medical diagnostic and treatment research and drug or pharmaceuticals or other treatment discovery, research and development purposes; designing and developing and providing temporary use of online searchable databases containing medical, pharmaceutical, biological, clinical and genomic information and medical and health information or records, molecular test results and patient specific data about or relating to humans for scientific research purposes; designing and developing and providing temporary use of non-downloadable computer software and algorithms for retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data and information on diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, patient specific data, molecular test results, data from clinical studies, and scientific research for use by physicians, clinicians and other healthcare professionals, laboratory personnel, consultants, scientists and other researchers for medical diagnostic and treatment and drug safety research and drug or pharmaceuticals or other treatment discovery, research and development; designing and developing and providing temporary use of non-downloadable software and algorithms for retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data, diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, records or data, and patient specific data, molecular test results, data from clinical studies, and scientific research for medical diagnostic and treatment research and drug or pharmaceuticals or other treatment discovery, research and development purposes; software as a Service (SaaS) used in research and consulting for enabling the retrieval, integration, correlation, analysis and interpretation of genomic data, sequencing data and molecular data, disease information, biomarker information, drug protocols, drug interactions, clinical profiles, and patient specific data, molecular test results, data from clinical studies, and scientific research and health and medical information, records or data for medical, diagnostic and treatment and drug safety research and drug or pharmaceuticals or other treatment discovery, research and development purposes; provision of non-downloadable mobile applications for mobile devices, such as smart phones and tablets, and non-downloadable web applications accessible through the Internet for accessing databases in the fields of medicine, health care, genomics, bioinformatics, pharmaceuticals and pharmaceutical safety, life sciences and biotechnology; data collection services for scientific research purposes in the fields of genomics, health care, pharmaceuticals, life sciences, bioinformatics, biotechnology and medicine; scientific research services for the retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data, diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, records or data, and patient specific data, molecular test results, data from clinical studies, and scientific research for medical diagnostic and treatment purposes; providing temporary use of non-downloadable computer software and algorithms for retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data and information on diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, patient specific data, molecular test results, data from clinical studies, and scientific research for use by physicians, clinicians and other healthcare professionals, laboratory personnel, consultants, scientists and other researchers for medical diagnostic and treatment purposes; providing temporary use of non-downloadable software and algorithms for retrieval, integration, correlation, analysis and interpretation of genomic data, sequencing data and molecular data, diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, records or data, and patient specific data, molecular test results, data from clinical studies, and scientific research for medical diagnostic and treatment purposes; providing information in the fields of life sciences, biotechnology, bioinformatics | ACTIVE | Nov 1, 2019 |
| 044 | Medical consulting services for the retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data, diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, records or data, and patient specific data, molecular test results, data from clinical studies, and scientific research for medical diagnostic and treatment purposes; providing online databases containing medical, pharmaceutical, biological, clinical, molecular, sequencing and genomic information, disease information, biomarker information and medical or health information or records about or relating to humans and patient specific data, molecular test results, and scientific research for medical diagnostic and treatment purposes; medical consulting services in the fields of health, medical care, biotechnology, bioinformatics, life sciences, pharmaceuticals and medicine; providing information in the fields of health, healthcare, pharmaceuticals and pharmaceutical safety, genetic testing for medical purposes; medical consulting services with respect to the treatment and diagnosis of individuals; providing pharmaceutical information, including information about drug safety and drug compatibility in relation to therapy and the treatment of individuals; medical consulting services in the fields of diagnostics and patient treatment and treatment protocols | ACTIVE | Nov 1, 2019 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Molecular Health GmbH
- Other trademarks owned by Molecular Health GmbH
- Other trademarks owned by Molecular Health GmbH
- Other trademarks in Class 009
- Other trademarks in Class 035
- Other trademarks in Class 036
- Other trademarks in Class 038
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named MH MOLECULAR HEALTH
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 13, 2026 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Jul 13, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 9, 2021 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Jun 8, 2021 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| May 25, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 25, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 25, 2021 | ALIE | ASSIGNED TO LIE | — |
| Feb 22, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 21, 2020 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 21, 2020 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 21, 2020 | CNRT | SU - NON-FINAL ACTION - WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 31, 2020 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Jul 10, 2020 | IUAF | USE AMENDMENT FILED | — |
| Jul 10, 2020 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Jan 15, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 14, 2020 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Jan 9, 2020 | EXT5 | SOU EXTENSION 5 FILED | — |
| Jan 9, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 13, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 11, 2019 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Jul 11, 2019 | EXT4 | SOU EXTENSION 4 FILED | — |
| Jul 11, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 15, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 11, 2019 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jan 11, 2019 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Jan 11, 2019 | EXT3 | SOU EXTENSION 3 FILED | — |
| Jan 11, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 13, 2018 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 11, 2018 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jul 11, 2018 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jul 11, 2018 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 11, 2018 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 21, 2018 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 20, 2018 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Feb 20, 2018 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Feb 5, 2018 | NREV | NOTICE OF REVIVAL - E-MAILED | — |
| Feb 5, 2018 | TPEX | SOU EXTENSION RECEIVED WITH TEAS PETITION | — |
| Feb 5, 2018 | PETG | PETITION TO REVIVE-GRANTED | — |
| Feb 5, 2018 | PROA | TEAS PETITION TO REVIVE RECEIVED | — |
| Jan 11, 2018 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jul 11, 2017 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| May 16, 2017 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 16, 2017 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 26, 2017 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 6, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 5, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 5, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 5, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 27, 2017 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 27, 2017 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 27, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 15, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 15, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 15, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 16, 2016 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 16, 2016 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 16, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 8, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 2, 2016 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Jun 1, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 27, 2016 | NWAP | NEW APPLICATION ENTERED | — |